

# Prevention of cardiovascular disease in current and former employees of the Ford motor company, Germany

<b>Submission date</b> 26/05/2011	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 28/07/2011	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 14/03/2023	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Cardiovascular diseases (CVD), including heart disease, heart attack and stroke, are a major cause of suffering and disability in many patients. Therefore, there is an urgent need for treatment strategies to prevent CVD, especially in healthy individuals at high risk for CVD. Decades of research have shown that CVD results from multiple risk factors, including smoking, high blood cholesterol, high blood pressure, obesity, chronic stress and depression. Treatment strategies for single risk factors are available, but, until now, only very few studies have targeted all of the aforementioned risk factors at the same time in a larger sample of healthy individuals at high risk for CVD. This study aims to fill this gap. The aim of this study is to find out whether the PreFord intervention reduces the risk of CVD.

### Who can participate?

Adults with no evidence of existing CVD, but at high risk for CVD in the future

### What does the study involve?

Participants are randomly allocated to either the PreFord intervention or routine care by their GPs. The PreFord intervention consists of 75 hours (total), divided into 30 sessions (2.5 hours each), two times a week, over a period of 15 weeks. It includes health education (e.g., the heart and vessels, healthy food, heart medication, etc), exercise, a smoking cessation programme if necessary, and LifeSkills, an approach to enhance stress resilience and social relationships at work and leisure time. The intervention is accompanied by a guideline-based drug treatment for high blood cholesterol and high blood pressure, if necessary. Well being, health behaviour and CVD risk factors are assessed before and after the intervention, and annually for 5 years. The intervention and each follow-up assessment are free of charge, and participants are free to join or leave the study whenever they wish.

### What are the possible benefits and risks of participating?

Not provided at time of registration

Where is the study run from?  
German Sports University Cologne

When is the study starting and how long is it expected to run for?  
August 2004 to July 2013

Who is funding the study?  
Bayer Vital (Germany), Pronova BKK (Germany) and AstraZeneca (Germany)

Who is the main contact?  
Prof. Hans-Georg Predel  
predel@dshs-koeln.de

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Hans-Georg Predel

**Contact details**  
German Sports University Cologne  
Cologne (Koeln)  
Germany  
50931  
-  
predel@dshs-koeln.de

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
N/A

## Study information

**Scientific Title**  
Multimodal intervention for primary prevention of cardiovascular disease in current and former employees of the Ford motor company, Germany - the PreFord trial

**Acronym**  
PreFord

**Study objectives**

A multimodal intervention for primary prevention of cardiovascular disease (CVD) will reduce multiple biological and psychosocial cardiac risk factors and cardiac events.

Re-evaluation of cardiovascular risk and cardiac events annually up to 5 years.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

1. North Rhine Medical Association (Aerztekammer North Rhine) Ethics Committee, 20/12/2004, ref: 2004079
2. Faculty of Medicine Ethics Committee, University of Cologne, 02/02/2004, ref: 03-217

### **Study design**

Two-armed randomized controlled clinical trial

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Other

### **Study type(s)**

Prevention

### **Participant information sheet**

Not available in web format, please use the contact details to request a patient information sheet

### **Health condition(s) or problem(s) studied**

Prevention of cardiovascular disease

### **Interventions**

Multimodal intervention for outpatients, two sessions a week in the afternoon for three months (75 hours total):

1. Health education
2. Exercise therapy
3. Smoking cessation programme
4. Stress management (LifeSkills)

### **Intervention Type**

Other

### **Phase**

Not Applicable

### **Primary outcome measure**

European Society of Cardiology risk score

## Secondary outcome measures

1. Health behaviour (physical fitness, smoking, BMI)
2. CVD risk factors, e.g. low-density-lipoprotein cholesterol (LDL-C), total cholesterol, triglycerides, blood pressure, diabetes mellitus, depression and anxiety (HADS), Type-D pattern (DS-14)

## Overall study start date

01/08/2004

## Completion date

31/07/2013

# Eligibility

## Key inclusion criteria

1. Adult men and women with no evidence for CVD and elevated risk according to the (European Society of Cardiology) ESC risk score > 5%
2. Informed consent

## Participant type(s)

Patient

## Age group

Adult

## Sex

Both

## Target number of participants

447

## Total final enrolment

447

## Key exclusion criteria

Severe somatic or psychiatric morbidity, e.g. malignancies, psychosis, drug addiction

## Date of first enrolment

01/08/2004

## Date of final enrolment

31/07/2013

# Locations

## Countries of recruitment

Germany

**Study participating centre**  
**German Sports University Cologne**  
Cologne (Koeln)  
Germany  
50931

## **Sponsor information**

**Organisation**  
German Sports University (Germany)

**Sponsor details**  
c/o Prof Dr HG Predel  
Cologne  
Germany  
50931

-  
predel@dshs-koeln.de

**Sponsor type**  
University/education

**Website**  
<https://www.dshs-koeln.de/wps/portal>

**ROR**  
<https://ror.org/0189raq88>

## **Funder(s)**

**Funder type**  
Industry

**Funder Name**  
Bayer Vital (Germany)

**Funder Name**  
Pronova BKK (Germany)

**Funder Name**

AstraZeneca (Germany)

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan**

Not provided at time of registration

**IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/02/2004		Yes	No
<a href="#">Results article</a>	results	01/02/2012		Yes	No
<a href="#">Results article</a>	results	01/09/2017		Yes	No
<a href="#">Other publications</a>	Secondary analysis	23/02/2023	14/03/2023	Yes	No